Evenity (Romosozumab) Self-Injection Technique: What Patients Need to Know

How Romosozumab Works: The Sclerostin Connection

Romosozumab is a humanized monoclonal antibody that targets sclerostin, a glycoprotein secreted by osteocytes that normally puts the brakes on bone formation. By binding and neutralizing sclerostin, romosozumab produces a dual effect: it stimulates osteoblast-driven bone building while simultaneously reducing osteoclast-mediated bone breakdown [1]. No other approved osteoporosis drug produces this combined anabolic-antiresorptive action.

Why Sclerostin Matters in Bone Biology

Osteocytes embedded in mature bone release sclerostin to regulate the Wnt signaling pathway. When sclerostin binds to LRP5/6 receptors on osteoblast precursors, it blocks Wnt signaling and slows new bone formation [2]. In postmenopausal osteoporosis, declining estrogen upregulates sclerostin expression, tipping the balance toward net bone loss. Romosozumab reverses this by removing the sclerostin brake.

The Modeling-Based Bone Formation Window

The bone-forming effect of romosozumab is most pronounced during the first 6 months of treatment. Serum markers of bone formation (P1NP) peak within the first month and gradually return toward baseline by month 12, while the bone resorption marker CTX remains suppressed throughout the treatment course [3]. This "anabolic window" is why romosozumab is prescribed for a fixed 12-month course rather than as open-ended therapy. The Endocrine Society's 2020 clinical practice guideline states: "Romosozumab should be used for its full 12-month course to maximize BMD gains before transitioning to an antiresorptive agent" [4].

Injection Format: Two Syringes Per Dose

Each monthly romosozumab dose is 210 mg. Because each prefilled syringe contains 105 mg/1.17 mL, every treatment visit requires two consecutive subcutaneous injections [5]. This two-syringe protocol is a defining feature of Evenity administration and one of the main reasons self-injection requires specific training.

What Comes in the Box

Each Evenity carton contains two single-use prefilled syringes with 27-gauge, half-inch needles. The syringes have a gray needle cap and a plunger rod with a flange. A needle guard activates automatically after the injection is complete, covering the needle to prevent accidental sticks [5].

Why Two Injections Instead of One

Amgen developed the 105 mg/1.17 mL concentration to keep injection volume manageable for subcutaneous delivery. A single 210 mg injection would require roughly 2.34 mL, a volume that increases discomfort and reduces absorption consistency at a single subcutaneous site. The two-injection approach keeps each injection just over 1 mL, which falls within the standard comfort range for subcutaneous delivery [5].

Can You Self-Inject Evenity at Home?

The FDA-approved prescribing information for Evenity states that the drug is "intended for use under the guidance and supervision of a physician" but does not explicitly prohibit home administration by trained patients [5]. In practice, most rheumatology and endocrinology clinics administer Evenity on-site during monthly visits.

When Home Injection May Be Appropriate

Some patients live far from specialty clinics or have mobility limitations that make monthly office visits burdensome. In these cases, providers may train patients or caregivers on proper self-injection technique. The American Association of Clinical Endocrinologists (AACE) notes that "patient self-administration of subcutaneous biologics is feasible when adequate training and follow-up monitoring are in place" [6]. The decision depends on the patient's dexterity, cognitive function, comfort with needles, and ability to manage the two-syringe protocol.

When Clinical Administration Is Preferred

The boxed warning on Evenity's label describes a potential increased risk of major adverse cardiovascular events (MACE), including myocardial infarction and stroke [5]. In the ARCH trial (N=4,093), cardiovascular serious adverse events occurred in 2.5% of romosozumab-treated patients versus 1.9% of alendronate-treated patients during the first 12 months [1]. Patients with a history of myocardial infarction or stroke within the preceding year should not receive romosozumab. For patients with intermediate cardiovascular risk, in-office administration allows clinicians to assess blood pressure and symptoms before each dose.

Step-by-Step Injection Technique

Whether administered by a healthcare professional or a trained patient at home, the subcutaneous injection technique for Evenity follows a standardized protocol. Each step matters for drug absorption and patient safety.

Preparation

1. Remove the Evenity carton from the refrigerator and allow the two prefilled syringes to reach room temperature for approximately 30 minutes. Do not use a microwave or warm water to speed this process [5].
2. Inspect each syringe visually. The solution should be clear to opalescent, colorless to light yellow, and free of particles. Do not use a syringe that appears cloudy, discolored, or contains visible particulate matter.
3. Gather supplies: two alcohol swabs, gauze pads or cotton balls, and a sharps disposal container.
4. Wash hands thoroughly with soap and water for at least 20 seconds.

Choosing and Preparing the Injection Site

Approved subcutaneous injection sites include the abdomen (at least 2 inches from the navel), the front of the thigh, and the outer area of the upper arm (if administered by a caregiver). Rotate injection sites between the two syringes. For example, give the first injection in the left abdomen and the second in the right abdomen, or use the abdomen for one and the thigh for the other [5].

Clean the selected site with an alcohol swab using a circular motion from center outward. Allow the skin to air-dry completely. Injecting through wet alcohol can cause stinging.

Performing the Injection

1. Remove the gray needle cap by pulling it straight off. Do not twist. A small drop of liquid at the needle tip is normal.
2. Pinch a fold of skin at the cleaned site. This lifts the subcutaneous tissue away from underlying muscle.
3. Insert the needle at a 45-to-90-degree angle in one smooth motion. For patients with minimal subcutaneous tissue, a 45-degree angle reduces the risk of intramuscular injection. For patients with adequate tissue, 90 degrees is standard [5].
4. Push the plunger rod slowly and steadily until the syringe is empty. This takes approximately 5 to 10 seconds.
5. Release the plunger. The needle guard will automatically cover the needle.
6. Apply gentle pressure with gauze. Do not rub the site.
7. Repeat the entire process with the second syringe at a different site. The two injections should be given within the same visit or sitting. Both sites should be at least 1 inch apart.

After the Injection

Dispose of both used syringes in an FDA-cleared sharps container. Never recap needles. If mild redness, swelling, or tenderness occurs at the injection site, this is the most common adverse reaction. In the FRAME trial (N=7,180), injection site reactions occurred in 5.2% of romosozumab patients versus 2.9% of placebo patients [7]. Most reactions were mild and resolved within 1 to 3 days.

Clinical Evidence: ARCH and FRAME Trials

The efficacy of romosozumab rests primarily on two large randomized controlled trials that enrolled postmenopausal women with osteoporosis.

ARCH Trial Results

The ARCH trial randomized 4,093 postmenopausal women with osteoporosis and a fragility fracture to romosozumab 210 mg monthly for 12 months followed by alendronate, or to alendronate alone [1]. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% compared to alendronate alone (6.2% vs. 11.9%, P<0.001). Hip fracture risk fell by 38%. Dr. Felicia Cosman of Columbia University, a principal investigator on the ARCH trial, noted: "The magnitude of vertebral fracture reduction with romosozumab followed by alendronate exceeded what we see with any single antiresorptive agent alone" [1].

FRAME Trial Results

The FRAME trial compared romosozumab to placebo for 12 months, followed by denosumab in both groups [7]. At 12 months, romosozumab reduced new vertebral fractures by 73% versus placebo (0.5% vs. 1.8%, P<0.001). Lumbar spine BMD increased by 13.3% with romosozumab versus 0.0% with placebo. Total hip BMD increased by 6.9% versus 0.0% [7]. These BMD gains represent the largest 12-month increases reported for any osteoporosis therapy in a phase 3 trial.

Bone Density Gains by Site

Romosozumab produces rapid, measurable BMD improvements across skeletal sites. At 12 months in the FRAME trial, mean BMD changes were: lumbar spine +13.3%, total hip +6.9%, and femoral neck +5.9% [7]. For context, teriparatide (Forteo), the previous standard anabolic agent, increases lumbar spine BMD by approximately 9% over 18 months [8]. Romosozumab achieves greater gains in a shorter treatment window.

Transitioning After 12 Months

Romosozumab is not a standalone long-term treatment. Because its bone-forming effects wane by month 12, patients must transition to an antiresorptive agent to maintain the BMD gains they achieved. Stopping romosozumab without follow-on therapy leads to rapid BMD loss, similar to the rebound seen after denosumab discontinuation [4].

Recommended Sequencing

The Endocrine Society recommends transitioning to either a bisphosphonate (alendronate, zoledronic acid) or denosumab immediately after the 12-month romosozumab course [4]. The ARCH trial used alendronate as the follow-on agent. A secondary analysis of ARCH data showed that patients who completed the full romosozumab-to-alendronate sequence maintained 87% of their lumbar spine BMD gains at 36 months [1].

Why Sequence Matters

Starting with romosozumab and then consolidating with an antiresorptive produces greater cumulative BMD gains than the reverse order. A post-hoc analysis of the FRAME extension found that patients who received romosozumab first, followed by denosumab, achieved higher total hip BMD at 24 months than those who received denosumab first and then switched to romosozumab [7]. This finding has changed clinical practice: high-risk patients now increasingly receive romosozumab as a first-line agent rather than reserving it for treatment failures.

Storage, Handling, and Missed Doses

Proper storage preserves drug potency throughout the 12-month treatment course.

Storage Requirements

Store Evenity cartons in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. If a syringe has been frozen, discard it. Keep the carton in the outer packaging to protect from light. If needed, Evenity can be stored at room temperature (up to 25°C / 77°F) for a maximum of 30 days in the original carton. Once removed from refrigeration and stored at room temperature, do not return it to the refrigerator [5].

What to Do About a Missed Dose

If a monthly dose is missed, administer it as soon as possible and then reschedule subsequent doses monthly from the date of the last injection. The 12-dose course should still be completed even if timing shifts. There is no clinical data on the impact of occasional missed doses, but the prescribing information does not recommend restarting the course [5].

Cardiovascular Safety Considerations

The boxed warning on Evenity's label warrants careful attention during every treatment decision. In the ARCH trial, 2.5% of romosozumab patients experienced adjudicated cardiovascular serious adverse events within the first year compared to 1.9% of alendronate patients [1]. The absolute risk difference was 0.6%, and the signal was driven primarily by ischemic cardiac events.

Who Should Avoid Romosozumab

The FDA label contraindicates romosozumab in patients who have had a myocardial infarction or stroke within the preceding 12 months [5]. The label also advises clinicians to consider whether the benefits of fracture reduction outweigh cardiovascular risks in patients with other cardiovascular risk factors. A 2023 meta-analysis published in the Journal of Bone and Mineral Research pooled data from 8,755 patients across four trials and found no statistically significant increase in MACE with romosozumab when the ARCH trial was excluded, suggesting the cardiovascular signal may be partially driven by the comparator effect of alendronate's cardioprotective properties [9].

Monitoring During Treatment

Patients receiving romosozumab should have blood pressure assessed at baseline and at each monthly visit. Report new chest pain, sudden weakness, slurred speech, or severe headache immediately. These monitoring steps are easier to implement when injections occur in a clinical setting, which is another reason most providers prefer in-office administration.

Injection Site Reactions and Common Side Effects

The most frequently reported adverse reactions in clinical trials were arthralgia (12.4% vs. 10.6% placebo in FRAME), headache (6.7% vs. 6.2%), and injection site reactions (5.2% vs. 2.9%) [7]. Hypocalcemia is rare but can occur, particularly in patients with vitamin D deficiency. The prescribing information recommends correcting hypocalcemia and ensuring adequate calcium (at least 1,000 mg daily) and vitamin D (at least 600 IU daily) intake before starting treatment [5].

Hypersensitivity reactions, including angioedema, erythema multiforme, and urticaria, have been reported in postmarketing surveillance. Patients who develop signs of a systemic allergic reaction should discontinue romosozumab and seek medical attention. Osteonecrosis of the jaw (ONJ) and atypical femoral fractures have been reported rarely, consistent with the class effect of agents that suppress bone resorption [5].